Search Results

Authors Jijun Chen , Liang Wang , Danhua Ma , He Zhang , Jiayan Fan , Hongyan Gao , Xinyu Xia , Wei Wu

He joined the faculty of Laval University School of Medicine in 1975 and then returned to join Duke’s faculty, where he remained as a James B. He and his laboratory members studied the mechanisms of action and regulation of hormones and neurotransmitters An authoritative and prolific scientist, with over 650 scientific publications, he is most beloved as Jie Zhang (1990) Thanks for listening to this podcast episode This short survey will help us understand

For postdoctoral training, he joined the laboratory of Dr. Strosberg AD in France, where he worked on the regulation of ß-adrenergic receptors. He is the Research director at INSERM with a specific interest in G protein-coupled receptors by developing He showed the formation of melatonin receptor heteromers in vitro and in vivo and their importance in He is a highly cited researcher – 2019 and 2020 identified by Clarivate Web of Science ™. Dr.

He did B.Sc. in biology at McGill University and received his Ph.D. under the mentorship of Dr. He did his postdoctoral training with Dr. Marc G. He has held four Canada Research Chairs since 2001 and was previously a Heart and Stroke Foundation of He was a recipient of Canada's Top 40 under 40 award in 2004 and received Queen Elizabeth II, Diamond Most recently, in 2021, he was elected as a Fellow of the Canadian Academy of Health Science (FCAHS).

He earned his master's degree in biotechnology from Jawaharlal Nehru University in India and it was during a biochemistry class where he learned about cell signaling that he became curious and wanted to learn working on GPCRs and their structural characterization at the Max Planck Institute of Biophysics where he Fascinated by GPCRs he wrote to Dr. Bob Lefkowitz and asked him if he could join his lab at Duke University. Dr.

He also directs a collaborative neuroscience R&D program with Servier (France) and is the co-founder company (2009-2012), where he was responsible all of the company’s discovery biology. He is an acknowledged expert in drug discovery, particularly in the field of psychiatry, where he has He has a degree and PhD in pharmacology from Queens' College, Cambridge and University College London He is also a corresponding member of NC-IUPHAR.

He did B.Sc. in biology at McGill University and received his Ph.D. under the mentorship of Dr. He did his postdoctoral training with Dr. Marc G. He has held four Canada Research Chairs since 2001 and was previously a Heart and Stroke Foundation of He was a recipient of Canada's Top 40 under 40 award in 2004 and received Queen Elizabeth II, Diamond Most recently, in 2021, he was elected as a Fellow of the Canadian Academy of Health Science (FCAHS).

Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences At Neurocrine, he initiated and led the effort to discover and develop orally active, nonpeptide GnRH Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions In addition, he is a member of the board of directors of the San Diego Entrepreneurs Exchange, a nonprofit organization that provides resources for early-stage start-ups, which he co-founded in [2009.]

David Gloriam is a Professor in Computational Receptor Biology at the University of Copenhagen where he He later identified physiological hormones of such under characterized ‘orphan’ receptors and functional He completed two postdocs in the UK at the EMBL-European Bioinformatics Institute and GlaxoSmithKline In 2018 he joined the University of Copenhagen, where he has received an ERC Starting Grant, Lundbeck He is one of the coordinators of recommendations to describe ligand bias towards signaling probes and

He works in a multidisciplinary Chemical Biology team based at the recently established US R&D hub in He then moved to Denmark, where he trained at the University of Copenhagen under supervision of Professor He is an avid proponent of close collaboration between industry and academia." Dr. His advice was to be ready for changes and to embrace opportunities as they arise. where he could immediately contribute due to his technical skills.

He joined the laboratory of Dr. William Cole at the University of Calgary in 2010 for his Ph.D. where he studied the molecular basis In 2015, He joined Dr. He has been also studying what aspects of GPCR signaling are regulated in a sex-selective manner and He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards

He subsequently enrolled in the Medical Scientist Training Program at The University of Chicago. Keith Moffat, he studied the structural mechanisms of bacterial photoreceptors using time-resolved Laue He was awarded his Ph.D. in 2004 and his MD in 2006. He then joined the Internal Medicine Residency training program at Duke University Medical Center. During his Cardiology fellowship, he trained in the lab of Dr. Robert J.

Timo De Groof studied Biochemistry and Biotechnology at the University of Ghent where he graduated in During his master's studies, he specialized in Biomedical Biotechnology and Structural Biology/Biochemistry From 2015 to 2019, he completed his Ph.D. in the Medicinal Chemistry group at VU University Amsterdam He currently is focusing on the development of nanobody-based immuno tracers as part of the IMI/EFPIA Moreover, he is closely involved in multiple projects where he focuses on the generation of nanobodies

Abstract Coming Soon About Bruno Giros "Bruno Giros' lab is dedicated to investigating how molecular changes and Marie Curie University in Paris and a short internship at Genentech Inc. in South San Francisco, he Research Fellow in 1987 in the INSERM Laboratory directed by Jean-Charles Schwartz in Paris, where he From 91 to 94, he was an assistant professor at Duke University in North Carolina, working with Marc Since 2008, he arrived at McGill University with a Canada Research Chair.

He obtained his B.S. in Chemistry from The University of Chicago in 1998 and subsequently enrolled in Keith Moffat, he studied the structural mechanisms of bacterial photoreceptors using time-resolved Laue He was awarded his PhD in 2004 and his MD in 2006. He then joined the Internal Medicine Residency training program at Duke University Medical Center. During his Cardiology fellowship, he trained in the lab of Dr. Robert J.

., he retired at the end of 2014 and since then has been writing papers on his final major project at During a joint postdoc with John W Daly at NIH and Solomon Snyder at Johns Hopkins, he developed the In 1988, he joined Lilly as a receptor biologist in charge of a high-throughput screening lab. He taught himself chemoinformatics as a way to optimize compound selection for screening, and in 1997 He supported the D1 PAM project in various roles from its inception in 2002 until selection of a clinical

He received his B.S. in Chemistry from Duke University in 2016 where he worked in the lab of Dr. He is currently finishing his Ph.D. in the lab of Dr. He primarily studies the chemokine receptor CXCR3 as it has three naturally occurring ligands and thus He hopes to continue his research on biased agonism at GPCRs with a particular focus on the treatment

He completed postdoctoral training at the Weizmann Institute. In 1983, he joined the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the He is currently the Senior Investigator and Chief of the Molecular Recognition Section, Laboratory of He adapts interdisciplinary approaches (synthesis, modeling, pharmacology) to study G protein-coupled He has published more than 800 scientific publications, with an H-index of 115.

Louis University in 1983, he subsequently trained in pharmacology (NIH), molecular biology, and psychiatry attending the lecture of a visiting professor on neurotransmission while in college in Montana, where he He was determined to work on psychiatric disorders and persevered even when he was told several times he would never make it as a basic scientist and would never publish anything important.

He joined the laboratory of Dr. William Cole at the University of Calgary in 2010 for his Ph.D. where he studied the molecular basis In 2015, He joined Dr. He has been also studying what aspects of GPCR signaling are regulated in a sex-selective manner and He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards

., 2012 Nobel Prize in Chemistry, which he shared with Dr. Brian Kobilka . Before we pressed record, I asked if I could call him Bob, and he answered that only his mom used to then pressed record, and we chatted for almost 2h about Bob’s career, discoveries, difficulties (yes, he ’s had some too), Nobel week, and his memoir that he just published in collaboration with Dr. His legacy lies in the numerous discoveries he and his team made in the GPCR field and in all those who

He obtained both his MS and Ph.D. in Neuroendocrine Physiology at Florida State University before completing He then moved to work in the pharmaceutical industry where he has held positions of increasing responsibility He currently leads a team that provides a mechanistic understanding of small molecule drug candidates He continues to pioneer in drug discovery studying GPCRs and other target classes.

He is passionate about developing more rational ways to understand and engineer biology. Sri previously worked at the Wyss Institute and Harvard, where he built numerous technologies in gene He helped build Gen9, a gene synthesis company, as a member of the SAB and was the first employee of He is a Searle Scholar (2015), NIH New Innovator (2014), and received his ScD in Biological Engineering He enjoys eating, getting outdoors, and traveling with his wife and two children. Dr.

He obtained both his MS and Ph.D. in Neuroendocrine Physiology at Florida State University before completing He then moved to work in the pharmaceutical industry where he has held positions of increasing responsibility He currently leads a team that provides a mechanistic understanding of small molecule drug candidates He continues to pioneer in drug discovery studying GPCRs and other target classes.

Instead, he ended up getting interested in membrane protein as he followed the biology of a bacterial Today he and his team are working on understanding receptor signaling in specialized cellular environments With over 2000 followers on Facebook and Twitter, he shares the latest available information on GPCR

Demet shared his journey of studying adhesion GPCRs, the challenges he faced, and the progress made in Yamina asked about Demet's career aspirations, to which he responded that he pursued science because he enjoyed it. conventions of proteins in the field, with Yamina expressing concern about the potential confusion caused by changes wouldn't change his past actions, as he believed they led him to his current fulfilling path.

He is a first-generation college graduate and academic. After spending two years at the Cleveland Institute of Art, he earned degrees in Biochemistry and Chemistry He then went on to earn a Ph.D. in Molecular Biophysics from Johns Hopkins University, followed by postdocs Cellular Pharmacology Department at the University of Miami Miller School of Medicine in 2016, where he

the National Institutes of Health in the Laboratory of Bioorganic Chemistry in Bethesda, MD, where he He completed his postdoctoral training at MIT and Harvard Med School in the lab of Hidde Ploegh , where he developed new applications of single-domain antibodies (nanobodies). He earned his Ph.D. in Chemistry at the University of Wisconsin-Madison in the lab of Sam Gellman on